Log in

Relevant bibliographies by topics / Castlemaine / Journal articles

To see the other types of publications on this topic, follow the link: Castlemaine.

Journal articles on the topic 'Castlemaine'

Author: Grafiati

Published: 4 June 2021

Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Castlemaine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Corbett, Margery. "An Account of his Excellence Roger Earl of Castlemaine's Embassy, from his Sacred Majesty James the IID. King of England, Scotland, France and Ireland &. To His Holiness Innocent XI." Antiquaries Journal 70, no. 1 (March 1990): 117–20. http://dx.doi.org/10.1017/s0003581500070359.

Full text

Abstract:

The historical circumstances of Lord Castlemaine's embassy are well known. James II, as the Roman Catholic monarch of Britain, wished to pay his respects to the Pope, Innocent XI, and to secure a papal ambassadorial representative to his kingdom. There must have been further urgent requests of a political nature. He sent Lord Castlemaine as ambassador, the husband of Barbara Villiers. The Pope was made anxious by the close ties of James with Louis XIV and was not eager to receive him; a private audience at the Vatican was granted on 19 April 1686 not long after his arrival. The public entry, postponed owing to the indisposition of the Pope, did not take place until 8 January 1687.

APA, Harvard, Vancouver, ISO, and other styles

2

Hodgkin, Edward E. "Expert systems in drug design: the Castlemaine project." European Journal of Pharmaceutical Sciences 4 (September 1996): S15. http://dx.doi.org/10.1016/s0928-0987(96)00024-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

DZELZAINIS, MARTIN. "MILTON'S OF TRUE RELIGION AND THE EARL OF CASTLEMAINE." Seventeenth Century 7, no. 1 (March 1992): 53–69. http://dx.doi.org/10.1080/0268117x.1992.10555335.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gardiner, A. B. "Dryden, Bower, Castlemaine, and the Imagery of Revolution, 1682-1687." Eighteenth-Century Life 25, no. 2 (April 1, 2001): 135–46. http://dx.doi.org/10.1215/00982601-25-2-135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Willman, Clive E. "Regional structural controls of gold mineralisation, Bendigo and Castlemaine goldfields, Central Victoria, Australia." Mineralium Deposita 42, no. 5 (July 15, 2006): 449–63. http://dx.doi.org/10.1007/s00126-006-0072-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Geradin, Damien, and Raoul Stewardson. "Trade and Environment: Some Lessons from Castlemaine Tooheys (Australia) and Danish Bottles (European Community)." International and Comparative Law Quarterly 44, no. 1 (January 1995): 41–71. http://dx.doi.org/10.1093/iclqaj/44.1.41.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cox, S. F., M. A. Etheridge, R. A. F. Cas, and B. A. Clifford. "Deformational style of the Castlemaine area, Bendigo‐Ballarat Zone: Implications for evolution of crustal structure in central Victoria." Australian Journal of Earth Sciences 38, no. 2 (May 1991): 151–70. http://dx.doi.org/10.1080/08120099108727963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Akbarkhiavi, Savalan Pour, and Monzur Alam Imteaz. "Using a new pressure index for water distribution systems upgradation improvement evaluation." Water Supply 16, no. 5 (April 18, 2016): 1339–48. http://dx.doi.org/10.2166/ws.2016.065.

Full text

Abstract:

Potable water distribution systems (WDS) require upgrade strategies based on a pre-defined time interval which is identified by the responsible water authorities. The main goal of a potable water system upgrade is maintaining the standard and acceptable level of service after the occurrence of increases in the serviced population, asset ageing, and/or development of the serviced area. Defining the level of service varies by location according to the codes and regulations adopted by the water authority. In general, two main factors are notable in planning of WDS upgrade strategies: (1) the ‘level of service’ and (2) the ‘upgrade cost’. In the presented paper, a new index has been introduced to evaluate the level of service for WDS from a pressure point of view. The new index that is presented in this paper is named the ‘Pressure Index (PI)’, and incorporates a number of water connections for five different pressure regimes. As a case study, three existing water network systems in the Castlemaine township area, located in central Victoria, Australia, have been investigated and the relationship between the ‘upgrade costs’ and improvement in PI factors is presented.

APA, Harvard, Vancouver, ISO, and other styles

9

Blaikie, Norman. "Book reviews : THEORY OF KNOWLEDGE AND ITS DISSEMINATION Harry Maddox Castlemaine, Freshet Press, 1993, vi + 167pp., $10. 00, (paperback)." Australian and New Zealand Journal of Sociology 31, no. 1 (March 1995): 115–17. http://dx.doi.org/10.1177/144078339503100108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fowler, T. J., and C. N. Winsor. "Evolution of chevron folds by profile shape changes: comparison between multilayer deformation experiments and folds of the Bendigo-Castlemaine goldfields, Australia." Tectonophysics 258, no. 1-4 (June 1996): 125–50. http://dx.doi.org/10.1016/0040-1951(95)00191-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Fowler, T. J., and C. N. Winsor. "Characteristics and occurrence of bedding-parallel slip surfaces and laminated veins in chevron folds from the Bendigo-Castlemaine goldfields: implications for flexural-slip folding." Journal of Structural Geology 19, no. 6 (June 1997): 799–815. http://dx.doi.org/10.1016/s0191-8141(97)00004-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Vasilyev, V. I., S. G. Palshina, A. I. Pavlovskaya, N. V. Kokosadze, B. D. Chaltsev, and L. A. Shornikova. "Idiopathic multicentric Castleman’s disease." Terapevticheskii arkhiv 92, no. 5 (June 5, 2020): 78–84. http://dx.doi.org/10.26442/00403660.2020.05.000440.

Full text

Abstract:

Idiopathic multicentric Castlemans disease is a rare lymphoproliferative disorder that has many similar laboratory, radiological, clinical and pathological manifestations with various conditions, including IgG4-related disease. Increased activity of cytokines, especially interleukin-6, leads to systemic inflammatory symptoms with the development of lymphadenopathy and rarely extranodal lesions. Histological changes in the lymph nodesin hyaline vascular and plasma cell variants of Castlemans disease are hardly distinguishable from the pattern of reactive, tumor and IgG4-related lymphadenopathy. Idiopathic multicentric Castlemans disease can be diagnosed only when infection with human herpesvirus-8 type and human immunodeficiency virus is excluded. In the article, the authors describe two cases of idiopathic multicentric Castlemans disease, including the first world literature description of extranodal damage of the hip muscle in this disorder. In addition, the authors gave a review of the literature on the main clinical, laboratory and morphological manifestations, which allow confirming the diagnosis of Castlemans disease.

APA, Harvard, Vancouver, ISO, and other styles

13

Chisholm, Karen M., and Mark D. Fleming. "Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population." American Journal of Clinical Pathology 153, no. 6 (February 29, 2020): 821–32. http://dx.doi.org/10.1093/ajcp/aqaa011.

Full text

Abstract:

Abstract Objectives Compare the morphologic, laboratory, and clinical features of asymptomatic and symptomatic Castleman disease in the pediatric population. Methods We reviewed clinical records and histopathology of patients with Castleman disease from 2 pediatric institutions. Results Of 39 patients with pediatric Castleman disease, 37 had unicentric disease, all classified with the hyaline vascular variant of Castleman disease, 8 of which were clinically symptomatic. These 8 patients demonstrated abnormal laboratory findings, including microcytic anemia, elevated erythrocyte sedimentation rate and C-reactive protein, and hypoalbuminemia. In addition, histopathologic evaluation showed that the 8 symptomatic cases had more hyperplastic germinal centers, fewer atrophic or regressed germinal centers, fewer mantle zones containing multiple germinal centers, reduced “onion skinning” of mantle zones, and fewer “lollipop” formations compared with the asymptomatic cases. Conclusions This series of pediatric Castleman disease showed that lymph nodes from asymptomatic patients generally demonstrated the more classic hyaline vascular histology, whereas those with symptoms could lack or have only focal classic findings. As such, reactive lymph nodes with subtle Castleman-like features should prompt clinical correlation to ensure proper diagnosis.

APA, Harvard, Vancouver, ISO, and other styles

14

Hinder, Hitz, Brugnolaro, and Stöckli. "Eine seltene Differentialdiagnose der zervikalen Lymphadenopathie." Praxis 100, no. 2 (January 1, 2011): 105–8. http://dx.doi.org/10.1024/1661-8157/a00413.

Full text

Abstract:

Wir beschreiben eine 15-jährige Patientin mit einer langsam wachsenden, leicht schmerzhaften Schwellung am Hals, ohne Entzündungszeichen und ohne Allgemeinsymptome. Sonographisch fanden sich zwei vergrösserte Lymphknoten mit erhaltener Hiluszeichnung. Mithilfe der Histologie konnte schliesslich die Diagnose eines Morbus Castleman vom hyalin vaskulären Typ gestellt werden. Es werden die Differentialdiagnose der Schwellung am Hals sowie Klinik, Diagnostik, Pathogenese und Therapie des M. Castleman beschrieben. Der Morbus Castleman ist eine seltene Differentialdiagnose der nicht infektiösen zervikalen Lymphadenopathie. Die Therapie des unizentrischen Morbus Castleman liegt in der chirurgischen Resektion. Bei Kontraindikationen ist alternativ eine Radiotherapie zu diskutieren. Multizentrische Formen sind Systemerkrankungen mit schlechter Prognose und müssen interdisziplinär behandelt werden.

APA, Harvard, Vancouver, ISO, and other styles

15

Vílchez León, Mariana, Melvin Cortés Mejía, Andrea Espinoza Artavia, and Kembly Webb Webb. "Enfermedad de castleman unicéntrica: revisión breve de una enfermedad poco conocida." Revista Medica Sinergia 4, no. 2 (February 1, 2019): 28–36. http://dx.doi.org/10.31434/rms.v4i2.197.

Full text

Abstract:

La enfermedad de Castleman es una entidad patológica rara, que abarca un grupo heterogéneo de desórdenes histopatológicos de los ganglios linfáticos. Puede clasificarse en enfermedad de Castleman unicéntrica, cuando se trata del crecimiento de un solo ganglio linfático o de ganglios linfáticos de una misma región, o en enfermedad de Castleman multicéntrica si afecta adenopatías de diferentes regiones ganglionares. Ambos tipos de enfermedad de Castleman difieren en cuanto a incidencia, epidemiología y curso clínico. La enfermedad de Castleman unicéntrica tiene una incidencia calculada en Estados Unidos entre 15.9 a 19.9 casos por millón personas-año, se presenta principalmente en personas jóvenes, alrededor de la tercera década de la vida y es más frecuente en mujeres. Los factores causales de esta patología son desconocidos. Las manifestaciones clínicas dependen de la variante histológica, siendo más frecuente la variante hialino vascular, que suele ser asintomática. El diagnóstico confirmatorio de la enfermedad de Castleman unicéntrica es histológico. La resección nodular completa es el tratamiento de elección, mientras que en las lesiones no resecables la radioterapia y la quimioterapia son opciones terapéuticas. El pronóstico de la enfermedad es benigno, con una mortalidad asociada a 10 años del 4% y porcentajes de curación que rondan el 95%.

APA, Harvard, Vancouver, ISO, and other styles

16

Wang, Wei, and L. Jeffrey Medeiros. "Castleman Disease." Surgical Pathology Clinics 12, no. 3 (September 2019): 849–63. http://dx.doi.org/10.1016/j.path.2019.03.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Paratore, D. Alexander, and Brian R. Herts. "Castleman Disease." Journal of Urology 194, no. 2 (August 2015): 529–30. http://dx.doi.org/10.1016/j.juro.2015.05.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Saeed-Abdul-Rahman, Ibrahiem, and Ali M. Al-Amri. "Castleman disease." Korean Journal of Hematology 47, no. 3 (2012): 163. http://dx.doi.org/10.5045/kjh.2012.47.3.163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

van Rhee, Frits, and Nikhil C. Munshi. "Castleman Disease." Hematology/Oncology Clinics of North America 32, no. 1 (February 2018): xiii—xiv. http://dx.doi.org/10.1016/j.hoc.2017.10.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Cronin, Danielle M. P., and Roger A. Warnke. "Castleman Disease." Advances in Anatomic Pathology 16, no. 4 (July 2009): 236–46. http://dx.doi.org/10.1097/pap.0b013e3181a9d4d3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Van Rhee, Frits, and Nikhil C. Munshi. "Castleman Disease." Hematology/Oncology Clinics of North America 32, no. 1 (February 2018): i. http://dx.doi.org/10.1016/s0889-8588(17)30182-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Dham, Anu, and Bruce A. Peterson. "Castleman disease." Current Opinion in Hematology 14, no. 4 (July 2007): 354–59. http://dx.doi.org/10.1097/moh.0b013e328186ffab.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Cohn, Jason E., Jing Zhou, and Amanda Hu. "Castleman Disease." Ear, Nose & Throat Journal 97, no. 7 (July 2018): 233–34. http://dx.doi.org/10.1177/014556131809700704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Cohn, Jason E., Jing Zhou, and Amanda Hu. "Castleman Disease." Ear, Nose & Throat Journal 97, no. 8 (August 2018): 233–34. http://dx.doi.org/10.1177/014556131809700819.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Genoni, M., D. De Lorenzi, M. Bogen, A. Sulmoni, C. Marone, M. Alerci, E. Pedrinis, and W. Müller. "Morbus Castleman." DMW - Deutsche Medizinische Wochenschrift 118, no. 37 (March 25, 2008): 1316–20. http://dx.doi.org/10.1055/s-2008-1059456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

H�lzle, F., A. Landers, C. Platz-Baudin, D. Basrei, and K. D. Wolff. "Morbus Castleman." Mund-, Kiefer- und Gesichtschirurgie 9, no. 2 (January 13, 2005): 121–25. http://dx.doi.org/10.1007/s10006-004-0592-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Schrock, A., I. Gutgemann, and S. Keiner. "Morbus Castleman." HNO 55, S01 (May 2007): E. http://dx.doi.org/10.1007/s00106-006-1415-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Hirt, R., U. Krause, and S. Knipping. "M. Castleman." HNO 60, no. 12 (April 27, 2012): 1123–26. http://dx.doi.org/10.1007/s00106-012-2522-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bleiber, Brigitte, Jan-Olaf Gebbers, and Rudolf Joss. "Morbus Castleman." Medizinische Klinik 95, no. 9 (September 2000): 527–32. http://dx.doi.org/10.1007/pl00002143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Takihara, Hiroshi, Genichiro Yamakawa, Yoshikazu Baba, Mutsuo Takahashi, and Tokuhiro Ishihara. "Castleman disease." Urology 41, no. 2 (February 1993): 162–64. http://dx.doi.org/10.1016/0090-4295(93)90173-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Baker, Turner S., Kristyne J. Gambino, Lawrence Schriefer, Jung-Yeon Lim, Karyn Meltz Steinberg, David C. Fajgenbaum, Alejandro Martín García-Sancho, and Minji Byun. "A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease." Blood Advances 2, no. 21 (November 7, 2018): 2959–63. http://dx.doi.org/10.1182/bloodadvances.2018023911.

Full text

Abstract:

Key Points FAS can be mutated in individuals diagnosed with unicentric and idiopathic multicentric Castleman disease. Defective lymphocyte apoptosis may be a pathological mechanism shared between Castleman disease and autoimmune lymphoproliferative syndrome.

APA, Harvard, Vancouver, ISO, and other styles

32

Moloney, Fiachra, Maria Twomey, John Hinchion, and Michael Maher. "Castleman Disease: An Unexpected Cause of a Solitary Pleural Mass." Case Reports in Radiology 2013 (2013): 1–3. http://dx.doi.org/10.1155/2013/130515.

Full text

Abstract:

Castleman disease (CD) is a rare benign lymphoproliferative disorder, the etiology of which is unclear. Clinically it may manifest as localized disease (unicentric) or disseminated disease (multicentric). CD occurs in the thorax in 70% of cases, abdomen and pelvis in 15%, and in the neck in 10–15% of cases. We present a case of a pleural mass located posteriorly in a paraspinal location, which was discovered incidentally in a 50-year-old man and was subsequently resected followed by an unexpected diagnosis of Castleman disease on histological examination. In this report, we review the clinical and histological findings in a rare presentation of Castleman disease and discuss the findings in this case as part of an overall review of the typical radiological findings seen in Castleman disease.

APA, Harvard, Vancouver, ISO, and other styles

33

Das, Partha Pratim, Sarmistha Biswas, Shekhar Kumar Mondal, and Md Daharul Islam. "Castlemans disease: a rare presentation of cervical Lymphadenopathy." Journal of Dhaka Medical College 23, no. 1 (March 26, 2015): 124–27. http://dx.doi.org/10.3329/jdmc.v23i1.22707.

Full text

Abstract:

Castlemans disease is a rare lymphoproliferative disorder. Castlemans disease is a disease which involves massive non-malignant proliferation of lymphoid tissues that usually presents as mediastinal masses as well as other groups of lymphnodes. That is why, sometimes, confusion may arise whether the lymphadenopathy is benign or malignant. However, some authors describes, histologically and prognostically Castlemans disease is distinct from malignant lymph-node hyperplasia. DOI: http://dx.doi.org/10.3329/jdmc.v23i1.22707 J Dhaka Medical College, Vol. 23, No.1, April, 2014, Page 124-127

APA, Harvard, Vancouver, ISO, and other styles

34

Uldrick, Thomas S., Mark N. Polizzotto, Karen Aleman, Kathleen M. Wyvill, Vickie Marshall, Denise Whitby, Victoria Wang, et al. "Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease." Blood 124, no. 24 (December 4, 2014): 3544–52. http://dx.doi.org/10.1182/blood-2014-07-586800.

Full text

Abstract:

Key PointsRituximab plus liposomal doxorubicin is active and tolerated in patients with symptomatic KSHV-associated multicentric Castleman disease. This is a safe and effective initial regimen for concurrent symptomatic KSHV-associated multicentric Castleman disease and Kaposi sarcoma.

APA, Harvard, Vancouver, ISO, and other styles

35

GÜNDOĞUŞ, Baran, Hatice TÜRKER, Rıza Serdar EVMAN, Sümeyye ALPARSLAN BEKİR, Özlem SOĞUKPINAR, Merve KARAMAN, Ayçim ŞEN, and Merve HÖRMET. "Castleman's Disease." Turkiye Klinikleri Archives of Lung 18, no. 2 (2017): 43–46. http://dx.doi.org/10.5336/archlung.2017-55200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Murinello, Ana Nicole Faria, Cristina Matos, and Fernando Nogueira. "Doença de Castleman: uma apresentação pouco frequente." Jornal Brasileiro de Pneumologia 37, no. 1 (February 2011): 129–32. http://dx.doi.org/10.1590/s1806-37132011000100018.

Full text

Abstract:

A doença de Castleman é uma doença linfoproliferativa rara, com envolvimento ganglionar localizado ou sistêmico, raramente atingindo o parênquima pulmonar. Relatamos o caso de um paciente imunocompetente, assintomático, com a variante histológica mais rara da doença, com apresentação nodular parenquimatosa. O paciente foi submetido a lobectomia, com evolução benigna. Nos últimos 10 anos, somente cinco casos de doença de Castleman com apresentação na forma de nódulo pulmonar único foram descritos na literatura. Este caso reforça a necessidade de inclusão da doença de Castleman no diagnóstico diferencial dos nódulos do pulmão, embora ela seja rara.

APA, Harvard, Vancouver, ISO, and other styles

37

Filliatre-Clement, L., H. Busby-Venner, C. Moulin, G. Roth-Guepin, and A. Perrot. "Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another." Case Reports in Hematology 2017 (2017): 1–3. http://dx.doi.org/10.1155/2017/9423205.

Full text

Abstract:

We describe a rare case of Castleman disease associated de novo with Hodgkin lymphoma. The incidence of Castleman disease is rare; only a few studies have described it in de novo association with Hodgkin lymphoma. The patient described here complained of unique evolutionary axillary adenopathy. A positron-emission tomography/computed tomography scan revealed hypermetabolic activity in this area. Diagnosis was based on a total excision biopsy of the adenopathy. The patient underwent complete remission with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy for treating Hodgkin lymphoma after surgical excision of the unicentric Castleman disease lesion.

APA, Harvard, Vancouver, ISO, and other styles

38

Butzmann, Alexandra, Joanna Przybyl, Kaushik Sridhar, Jyoti Kumar, Nivaz Brar, James L. Zehnder, Roger A. Warnke, and Robert S. Ohgami. "A Meta-Analysis of Genetic Abnormalities and Next Generation Sequencing of Primary Cases of Castleman Disease." Blood 134, Supplement_1 (November 13, 2019): 5227. http://dx.doi.org/10.1182/blood-2019-131261.

Full text

Abstract:

Castleman disease is a rare lymphoproliferative disorder known to represent at least four distinct clinico-pathologic sub-types. Large advancements in our clinical and histopathologic description of these diverse diseases have been made, resulting in subtyping based on degree of nodal involvement (unicentric versus multicentric) and according to viral infection (human herpes virus 8 - HHV8 and Human Immunodeficiency Virus - HIV). However, we continue to lack a foundational understanding of the biologic mechanisms driving at least a subset of patients with these diseases. In recent years, significant molecular and genetic abnormalities that may be associated with this disease have been described; yet we are still unclear as to a unified vision of what loci and genes are involved in at least a subset of cases of Castleman disease. In our study we performed a meta-analysis of all cases (unicentric and multicentric) of Castleman disease described in literature to date, and correlate cytogenetic, molecular and genetic abnormalities with disease subtypes, phenotypes and clinical outcomes. We further performed targeted DNA deep sequencing and RNA-sequencing on a cohort of Castleman Disease cases. Our results demonstrate that genetic abnormalities in the MAPK-pathways, PI3K-pathway and Interleukin signaling are frequent in unicentric Castleman disease, whereas abnormalities in DNA methylation are seen more commonly in idiopathic multicentric Castleman disease, along with abnormalities in MAPK-pathways. We conclude that UCD and iMCD may share similar pathways of MAPK pathogenesis but can also be distinguished by cytokine and other DNA modification pathways that differ. Disclosures Ohgami: Agilent technologies: Other: received support/funding.

APA, Harvard, Vancouver, ISO, and other styles

39

Oshitari, Toshiyuki, Fusae Kajita, Aya Tobe, Makiko Itami, Jiro Yotsukura, Takayuki Baba, and Shuichi Yamamoto. "Refractory Uveitis in Patient with Castleman Disease Successfully Treated with Tocilizumab." Case Reports in Ophthalmological Medicine 2012 (2012): 1–3. http://dx.doi.org/10.1155/2012/968180.

Full text

Abstract:

Although multicentric Castleman disease is a rare but life-threatening disease, eye complications are extremely uncommon. We present a case of refractory uveitis accompanied with Castleman disease successfully treated with tocilizumab. A 58-year-old man with Castleman disease was introduced for refractory uveitis to Chiba University Hospital. Large cells were detected in the anterior chamber and increased vascular permeability of retinal vessels has been found in both eyes. Although the patient was treated with oral and eye drop steroid treatment, the uveitis symptoms had not decreased. The serum levels of CRP and IL-6 were increased. The level of IL-6 concentration in the anterior chamber was the same as the serum level of IL-6. The humanized anti-IL-6 receptor-antibody (tocilizumab) was administrated for the patient because of poor general condition. After tocilizumab treatment, large cells in the anterior chamber were undetectable and vascular permeability was improved in FA. The serum levels of CRP and IL-6 decreased and the general condition improved. The side effect of tocilizumab was not observed during the treatment. Tocilizumab treatment was significantly effective for uveitis accompanied with Castleman disease. Although it is extremely rare, uveitis accompanied with Castleman disease may be one of the hallmarks to consider tocilizumab treatment.

APA, Harvard, Vancouver, ISO, and other styles

40

Stojsic, Jelena, Svetlana Krstic, Dragan Subotic, Tatjana Eminovic, and Jelena Radojicic. "Incidentally detected Castleman disease in a patient with allergic rhinosinu sitis." Srpski arhiv za celokupno lekarstvo 136, no. 1-2 (2008): 46–49. http://dx.doi.org/10.2298/sarh0802046s.

Full text

Abstract:

INTRODUCTION Castleman disease was for the first time described in 1956 as a mediastinal tumour mass. Etiology of this disease is still unknown. The disease can be solitary and multicentric or rarely of a mixed type. The former is often of hyaline vascular type, while the latter is of plasma cell type. CASE REPORT Castleman disease was diagnosed in a 26-year old male patient when a well defined shadow was incidentally detected in the middle lobe of the right lung. A year before, he was diagnosed with allergic rhinitis to Ambrosia. Two years after surgery the patient was feeling well, and was without any recurrence, however, allergic rhinitis still persisted. CONCLUSION Castleman disease can occur in any organ containing lymph tissues. Most frequently the disease is described as mediastinal, rarely as an intrapulmonary tumorous mass, and it is most frequently seen in younger persons. The solitary type of Castleman disease is surgical treatable with a prospect of good prognosis, while the multicentric and mixed types recur despite treatment with cortisone, irradiation and cytostatics. As the association between Castleman disease and allergic diseases has not been confirmed up-tonow, it could be concluded that this patient suffered from two separated diseases.

APA, Harvard, Vancouver, ISO, and other styles

41

Iskandar, Andrew, Andrew Hwang, and Constantin A. Dasanu. "Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: Responding to rituximab." Journal of Oncology Pharmacy Practice 25, no. 8 (November 28, 2018): 2016–18. http://dx.doi.org/10.1177/1078155218816775.

Full text

Abstract:

Castleman disease is a rare B-cell lymphoproliferative disorder characterized by lymph node enlargement with or without constitutional signs. Herein, we describe a unique patient with multicentric Castleman disease and retroviral infection who presented with a sudden onset of constitutional signs and was found to have severe warm-antibody autoimmune hemolytic anemia. Rituximab monotherapy yielded an excellent clinical response. We aim to inform the medical community of this rare paraneoplastic phenomenon in patients with Castleman disease and its effective management. Prompt recognition of this entity may help avoid costly diagnostic workups, excessive blood transfusions, and lengthy hospital stays.

APA, Harvard, Vancouver, ISO, and other styles

42

Mazumder, Sujaya, Raji Tejas Naidu, Susan Cherian, Sruthi Mayura, and Uma Pankaj Chaturvedi. "An Unusual Presentation of Idiopathic Multicentric Castleman Disease: The Great Masquerader." Annals of Pathology and Laboratory Medicine 7, no. 9 (September 25, 2020): C119–122. http://dx.doi.org/10.21276/apalm.2844.

Full text

Abstract:

Castleman disease is an uncommon, non-clonal, lymphoproliferative disorder characterized by lymphadenopathy and symptoms related to hypercytokinemia. Clinically it is classified as unicentric and multicentric disease. Multicentric disease is further subclassified as HHV- 8 associated disease and idiopathic disease, which is the rarest subtype. The incidence of idiopathic disease is estimated to be 5 per million person years. The diagnosis of Idiopathic Multicentric Castleman disease is complicated by an array of clinical mimics and non-specific symptoms. We report a rare case of Idiopathic Multicentric Castleman disease in a young female where a detailed pathological work up helped to secure the diagnosis and exclude its mimics.

APA, Harvard, Vancouver, ISO, and other styles

43

Fu, Ruiying, Yingzhi He, and Liang Wang. "Castleman disease with rapidly progressive pemphigus: a case report." Aging Pathobiology and Therapeutics 2, no. 4 (December 31, 2020): 223–25. http://dx.doi.org/10.31491/apt.2020.12.044.

Full text

Abstract:

Paraneoplastic pemphigus (PNP) is a rare autoimmune disorder of the skin, which is associated with various underlying benign or malignant neoplasms. We report a case of a 34-year-old man with rapidly progressed and extensive skin lesions, and significant weight loss. He was diagnosed as pemphigus Vulgaris with a skin biopsy firstly, then the PET/CT scan showed a retroperitoneal mass. Pathological examination of the retroperitoneal mass confirmed the diagnosis of Castleman disease with paraneoplastic pemphigus. By reporting this case, we aimed to improve the clinical alertness and awareness of Castleman disease in patients characterized by paraneoplastic pemphigus. Keywords: Paraneoplastic pemphigus, Castleman disease, paraneoplastic syndrome, hematologic malignancies

APA, Harvard, Vancouver, ISO, and other styles

44

Nunes, Maria Brito, Samuel Rotman, Francois-Regis Duss, and Matthieu Halfon. "HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis." BMJ Case Reports 13, no. 1 (January 2020): e231844. http://dx.doi.org/10.1136/bcr-2019-231844.

Full text

Abstract:

Multicentric Castleman disease is a rare polyclonal lymphoproliferative disorder mainly associated with two renal manifestations: thrombotic microangiopathy and amyloidosis. Nevertheless, we report here a case of human herpes virus-8 negative multicentric Castleman disease with membranous proliferative glomerulonephritis and extracapillary proliferation. A patient was successfully treated with corticosteroids, anti-CD20 and cyclophosphamide therapy.

APA, Harvard, Vancouver, ISO, and other styles

45

Marcelin, Anne-Geneviève, Laurent Aaron, Christine Mateus, Emmanuel Gyan, Isabelle Gorin, Jean-Paul Viard, Vincent Calvez, and Nicolas Dupin. "Rituximab therapy for HIV-associated Castleman disease." Blood 102, no. 8 (October 15, 2003): 2786–88. http://dx.doi.org/10.1182/blood-2003-03-0951.

Full text

Abstract:

Abstract To assess the clinical benefit of rituximab for HIV-associated Castleman disease, 5 patients infected with HIV with histologic-proven Castleman disease were prospectively enrolled to receive 4 infusions of rituximab. Clinical and biologic parameters (C-reactive protein, CD19 cell count, Kaposi sarcoma–associated herpesvirus [KSHV] viral load in peripheral blood mononuclear cells) were assessed before and at different time points following rituximab infusions. Two patients died very quickly after the beginning of rituximab therapy with no effect on both KSHV viral load and CD19 cell count. Three of 5 patients were considered in complete remission with no more clinical symptoms related to Castleman disease with a follow-up of 4 to 14 months. In 2 cases, clinical remission correlated with a dramatic decrease of KSHV viral load and C-reactive protein levels and a transitory but sharp decrease of CD19 cell count. In 2 responders, we observed an aggravation of Kaposi sarcoma. Our preliminary results suggest that rituximab may be effective in controlling Castleman disease in a subset of patients, although it may exacerbate concomitant Kaposi sarcoma.

APA, Harvard, Vancouver, ISO, and other styles

46

Marcu, Radu Dragos, Arsenie Dan Spinu, Bogdan Socea, Maria Oana Bodean, Camelia Cristina Diaconu, Florina Vasilescu, Tiberiu Paul Neagu, and Ovidiu Gabriel Bratu. "Castleman�s Disease - Clinical, Histological and Therapeutic Features." Revista de Chimie 69, no. 4 (May 15, 2018): 823–30. http://dx.doi.org/10.37358/rc.18.4.6208.

Full text

Abstract:

Castleman�s disease (CD) is a rare and benign lymphoproliferative pathology, characterized by lymphoid tissue hyperplasia, process that can occur at any site of the lymphoid chain. The purpose of this paper is to review the existing data regarding Castleman�s disease etiopathogenesis and treatment. Considering the extent of the lymphoid tissue involvement Castleman�s disease can be classified as unicentric (UCD) and multicentric (MCD). Another classification of this pathology is based on the histopathological features: hyaline vascular CD (90% of cases), plasma cell CD (less than 10%) and mixed cell type. Patients with UCD have good prognosis, the gold standard treatment being complete surgical excision. The multicentric type in contrast to UCD has a worse prognosis and associates the risk of evolving to lymphoma. Over the years different therapeutic strategies have been applied in the management of multicentric Castleman�s disease: glucocorticoids, chemotherapy, antiviral agents and monoclonal antibodies that target CD (cluster of differentiation) 20, interleukin -6 (IL-6) and IL-6 receptors. Castleman�s disease is a rare and complex pathology, whose etiopathogenesis is still incompletely elucidated. In the past few years the overall survival and progression free survival has significantly increased, due to different therapeutic options that have emerged, options that have constantly offered better and better results. Further investigation regarding the chemical interactions between different receptors and therapeutic molecules, understanding the mechanism of action and the potential benefits of each therapeutic agent may prove useful in clinical practice for treating CD.

APA, Harvard, Vancouver, ISO, and other styles

47

BIÇAKÇIOĞLU, Pınar, Selim Şakir Erkmen GÜLHAN, Leyla Nesrin ACAR, Yetkin AĞAÇKIRAN, Şeref ÖZKARA, Sadi KAYA, and Nurettin KARAOĞLANOĞLU. "Intrathoracic Castleman disease." TURKISH JOURNAL OF MEDICAL SCIENCES 44 (2014): 197–202. http://dx.doi.org/10.3906/sag-1304-38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

KAMATA, Tsugumasa, Norifumi HATTORI, Katsumi KOSHIKAWA, Hiroyuki YOKOYAMA, Kenji TANIGUCHI, and Hiroyuki SUENAGA. "PELVIC CASTLEMAN DISEASE." Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 69, no. 9 (2008): 2423–28. http://dx.doi.org/10.3919/jjsa.69.2423.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Zhang, Ke Ren, and Hui Min Jia. "Mesenteric Castleman disease." Journal of Pediatric Surgery 43, no. 7 (July 2008): 1398–400. http://dx.doi.org/10.1016/j.jpedsurg.2008.02.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Paez Ardila, Hugo, Micela Rosado Rodriguez, and Oscar Ricardo Baron Castro. "Enfermedad de Castleman." Acta Médica Colombiana 42, no. 4 (December 15, 2017): 247. http://dx.doi.org/10.36104/amc.2017.678.

Full text

Abstract:

Se presenta el caso de una mujer de 67 años de edad, con cuadro clínico de dolor abdominal, a quien se le realiza un abordaje quirúrgico el cual no es conclusivo y que por persistencia de la sintomatología y el hallazgo radiológico de adenomegalias mesentéricas, se decide tomar una biopsia ganglionar, con la cual se realiza el diagnóstico de Enfermedad de Castleman (EC) variante hialino-vascular; La EC es un trastorno linfoproliferativo caracterizado por una hiperplasia ganglionar gigante, su principal compromiso es mediastinal (70% de los casos) y a pesar de que el compromiso abdominal es infrecuente (15%)2, es un diagnóstico que se debe considerar en el paciente con dolor abdominal y adenomegalias.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!